Ryaltris is a drug owned by Glenmark Specialty Sa. It is protected by 15 US drug patents filed from 2022 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 03, 2038. Details of Ryaltris's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11679210 | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Sep, 2038
(13 years from now) | Active |
| US12064442 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10016443 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10517880 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US9750754 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US9078923 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10561672 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US9370483 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10376526 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US9937189 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10765686 | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10758550 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10646500 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US11400101 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
| US10548907 | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ryaltris's patents.
Latest Legal Activities on Ryaltris's Patents
Given below is the list of recent legal activities going on the following patents of Ryaltris.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Feb, 2024 | US10765686 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Feb, 2024 | US10758550 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Dec, 2023 | US9370483 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Oct, 2023 | US10646500 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Aug, 2023 | US10561672 |
| Post Issue Communication - Certificate of Correction | 31 Jul, 2023 | US10016443 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jul, 2023 | US10548907 |
| Electronic Review Critical | 29 Jun, 2023 | US10016443 |
| Email Notification Critical | 29 Jun, 2023 | US10016443 |
| Mail Pet Dec Routed to Certificate of Corrections Branch | 28 Jun, 2023 | US10016443 |
FDA has granted several exclusivities to Ryaltris. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ryaltris, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ryaltris.
Exclusivity Information
Ryaltris holds 1 exclusivities. All of its exclusivities have expired in 2025. Details of Ryaltris's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
Several oppositions have been filed on Ryaltris's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Ryaltris's generic, the next section provides detailed information on ongoing and past EP oppositions related to Ryaltris patents.
Ryaltris's Oppositions Filed in EPO
Ryaltris has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 29, 2022, by Ter Meer Steinmeister & Partner Patentanwälte Mbb. This opposition was filed on patent number EP14781946A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP14781946A | Mar, 2022 | Ter Meer Steinmeister & Partner Patentanwälte mbB | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Ryaltris is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ryaltris's family patents as well as insights into ongoing legal events on those patents.
Ryaltris's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ryaltris's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 03, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ryaltris Generics:
There are no approved generic versions for Ryaltris as of now.
About Ryaltris
Ryaltris is a drug owned by Glenmark Specialty Sa. It is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate. Ryaltris uses Mometasone Furoate; Olopatadine Hydrochloride as an active ingredient. Ryaltris was launched by Glenmark Speclt in 2022.
Approval Date:
Ryaltris was approved by FDA for market use on 13 January, 2022.
Active Ingredient:
Ryaltris uses Mometasone Furoate; Olopatadine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Mometasone Furoate; Olopatadine Hydrochloride ingredient
Treatment:
Ryaltris is used for treating seasonal allergic rhinitis through nasal administration of a combination of olopatadine hydrochloride and mometasone furoate.
Dosage:
Ryaltris is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025MG/SPRAY;0.665MG/SPRAY | SPRAY, METERED | Prescription | NASAL |